Home

Medtronic today announced the start of a prospective, observational, global, multicentre, real-world, post-market study to evaluate the safety and effectiveness of the Valiant Navion thoracic stent graft system in the treatment of thoracic aortic dissection. The first patient procedure in the DISSECT-N study was performed at Northwell Health in New York, USA by Derek Brinster, director of Aortic Surgery.

“Treatment of aortic dissection is often challenging, especially as patients with fragile aortas have different needs. The Valiant Navion CoveredSeal configuration, designed with fragile aortic tissue in mind, can be especially helpful in treating this condition,” said Ross Milner, director of the Center for Aortic Diseases at the University of Chicago Medicine in Chicago, USA and US principal investigator for the DISSECT-N study. “I believe the DISSECT-N study—one of the larger prospective aortic dissection repair studies, which includes independent core-lab imaging review—will offer critical contemporary insights about TEVAR use in patients with various types of thoracic aortic dissection.”

The DISSECT-N study will enrol at least 200 patients with an acute or chronic thoracic aortic dissection across approximately 45 sites in North America, Europe, and Asia Pacific. The primary endpoint is composite safety and effectiveness, including technical procedure success and freedom from major adverse events (MAEs) reported up to one month following the index procedure. Patients will be followed for three years. Primary investigators are Dr. Milner and Robin Heijmen, M.D., Ph.D., cardiothoracic surgeon at St. Antonius Hospital in the Netherlands.

“Thoracic aortic dissection is dangerous, with some cases leading to severe internal bleeding or irreversible organ damage; with the Valiant Navion system, more patients with aortic dissection are eligible for thoracic endovascular aneurysm repair (TEVAR),” said Robin Heijmen (St Antonius Hospital, Nieuwegein, the Netherlands), European principal investigator for the DISSECT-N study. “I am pleased to support the generation of real-world evidence in this landmark study, which I believe will help enable the clinical community to optimally treat patients with thoracic aortic dissection using this technology.”

“There remains a significant clinical unmet need in treating thoracic dissection, and we are dedicated to improving the care for these patients through an endovascular approach,” said John Farquhar, vice president and general manager of the Aortic business, which is part of the Cardiac and Vascular Group at Medtronic. “With the DISSECT-N study, we hope to further support the Valiant Navion system as a less invasive approach to treating this condition.”

The low-profile Valiant Navion system received US Food and Drug Administration approval in October 2018, CE mark in November 2018, and approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan in September 2019.

Source VascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: Medtronic begins real-world, post-market study of Valiant Navion in patients with thoracic aortic dissection

Chia sẽ qua google bài: Medtronic begins real-world, post-market study of Valiant Navion in patients with thoracic aortic dissection

Chia sẽ qua twitter bài: Medtronic begins real-world, post-market study of Valiant Navion in patients with thoracic aortic dissection

Chia sẽ qua MySpace bài: Medtronic begins real-world, post-market study of Valiant Navion in patients with thoracic aortic dissection

Chia sẽ qua LinkedIn bài: Medtronic begins real-world, post-market study of Valiant Navion in patients with thoracic aortic dissection

Chia sẽ qua stumbleupon bài: Medtronic begins real-world, post-market study of Valiant Navion in patients with thoracic aortic dissection

Chia sẽ qua icio bài: Medtronic begins real-world, post-market study of Valiant Navion in patients with thoracic aortic dissection

Chia sẽ qua digg bài: Medtronic begins real-world, post-market study of Valiant Navion in patients with thoracic aortic dissection

Chia sẽ qua yahoo bài: Medtronic begins real-world, post-market study of Valiant Navion in patients with thoracic aortic dissection

Tin tức liên quan

Vesteck completes first-in-human use of several Suture-Tight devices

Age is just a number: Individual patient data meta-analysis probes safety of CEA in the elderly

Artificial intelligence can predict risk of complications after endovascular aneurysm repair

Bluegrass Vascular announces Journal of Vascular Surgery paper reporting use of Surfacer system

Vascular access creation: EndoAVF keeps future options open, but is not a replacement for surgical fistulas

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.